Cathie's Ark LogoCathie's Ark
BEGIN TYPING TO SEARCH BY TICKER
Trading Floor Community IconFrom the Trading Floor:
Fate Therapeutics Inc Logo

ARKG Holdings of Fate Therapeutics (FATE) - Updated Daily

Lock IconJoin Premium Plan
The Bucket Report Icon
Download ARK WatchlistsDownload ARK holdings as watchlists that can be imported into TradingView and Interactive Brokers
Date
Direction
Shares
Fund Weight
Fund
February 25, 2022BUY23.351k0.0216%ARKG
February 24, 2022BUY6.353k0.0061%ARKG
February 23, 2022BUY103.763k0.0957%ARKG
February 22, 2022BUY86.612k0.0795%ARKG
December 15, 2021BUY71.797k0.0678%ARKG

Key Statistics

DateMay 04, 2022Revenue
Expected0
Actual$18.41m
EPS
Expected-$0.76
Actual-$0.68
🕵🏼Found In🏷Last Price
ARKGARKK$23.10
⚖️Weighting🧢Market Cap
3.86%$2.23b
🏋🏿‍♂️Weight Rank In ARKG🧮Price to Sales
635.36
🏋️‍♀️Weight Rank Across All Funds🌏Country
19🇺🇸United States
💳ARK Estimated Cost Average🎫ARK Ownership Percent
$47.304.59%
Description
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company's immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Company's immuno-regulatory product candidates include ProTmune™, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease. Fate Therapeutics is headquartered in San Diego, CA.
Website
www.fatetherapeutics.com

Research Notes and Commentary for FATE

January 29, 2021

Ark Trades and Storylines

Trading Floor
Reported excellent Phase 1 clinical trial results for it's experimental CAR-NK therapy on...